Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.

Sherif Farag, Amy S. Ruppert, Krzysztof Mrózek, Andrew J. Carroll, Mark J. Pettenati, Michelle M. Le Beau, Bercedis L. Peterson, Bayard L. Powell, Howard Ozer, Richard T. Silver, Richard A. Larson, Clara D. Bloomfield

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-alpha treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-alpha alone or together with IFN-gamma or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19% of sole Ph+ patients, compared to 23 and 18%, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with 'high-risk' secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38%, respectively. On multivariable analysis, only age (P

Original languageEnglish (US)
Pages (from-to)143-151
Number of pages9
JournalInternational Journal of Oncology
Volume25
Issue number1
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon-alpha
Chromosome Aberrations
Leukemia
Neoplasms
Cytogenetics
Survival
Cytarabine
Interferon-gamma
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha : a Cancer and Leukemia Group B study. / Farag, Sherif; Ruppert, Amy S.; Mrózek, Krzysztof; Carroll, Andrew J.; Pettenati, Mark J.; Le Beau, Michelle M.; Peterson, Bercedis L.; Powell, Bayard L.; Ozer, Howard; Silver, Richard T.; Larson, Richard A.; Bloomfield, Clara D.

In: International Journal of Oncology, Vol. 25, No. 1, 07.2004, p. 143-151.

Research output: Contribution to journalArticle

Farag, S, Ruppert, AS, Mrózek, K, Carroll, AJ, Pettenati, MJ, Le Beau, MM, Peterson, BL, Powell, BL, Ozer, H, Silver, RT, Larson, RA & Bloomfield, CD 2004, 'Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.', International Journal of Oncology, vol. 25, no. 1, pp. 143-151.
Farag, Sherif ; Ruppert, Amy S. ; Mrózek, Krzysztof ; Carroll, Andrew J. ; Pettenati, Mark J. ; Le Beau, Michelle M. ; Peterson, Bercedis L. ; Powell, Bayard L. ; Ozer, Howard ; Silver, Richard T. ; Larson, Richard A. ; Bloomfield, Clara D. / Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha : a Cancer and Leukemia Group B study. In: International Journal of Oncology. 2004 ; Vol. 25, No. 1. pp. 143-151.
@article{fd2910b8eff3477fad95e0347702c036,
title = "Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.",
abstract = "Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-alpha treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-alpha alone or together with IFN-gamma or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19{\%} of sole Ph+ patients, compared to 23 and 18{\%}, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with 'high-risk' secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38{\%}, respectively. On multivariable analysis, only age (P",
author = "Sherif Farag and Ruppert, {Amy S.} and Krzysztof Mr{\'o}zek and Carroll, {Andrew J.} and Pettenati, {Mark J.} and {Le Beau}, {Michelle M.} and Peterson, {Bercedis L.} and Powell, {Bayard L.} and Howard Ozer and Silver, {Richard T.} and Larson, {Richard A.} and Bloomfield, {Clara D.}",
year = "2004",
month = "7",
language = "English (US)",
volume = "25",
pages = "143--151",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha

T2 - a Cancer and Leukemia Group B study.

AU - Farag, Sherif

AU - Ruppert, Amy S.

AU - Mrózek, Krzysztof

AU - Carroll, Andrew J.

AU - Pettenati, Mark J.

AU - Le Beau, Michelle M.

AU - Peterson, Bercedis L.

AU - Powell, Bayard L.

AU - Ozer, Howard

AU - Silver, Richard T.

AU - Larson, Richard A.

AU - Bloomfield, Clara D.

PY - 2004/7

Y1 - 2004/7

N2 - Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-alpha treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-alpha alone or together with IFN-gamma or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19% of sole Ph+ patients, compared to 23 and 18%, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with 'high-risk' secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38%, respectively. On multivariable analysis, only age (P

AB - Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-alpha treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-alpha alone or together with IFN-gamma or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19% of sole Ph+ patients, compared to 23 and 18%, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with 'high-risk' secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38%, respectively. On multivariable analysis, only age (P

UR - http://www.scopus.com/inward/record.url?scp=21644490136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644490136&partnerID=8YFLogxK

M3 - Article

C2 - 15201999

AN - SCOPUS:21644490136

VL - 25

SP - 143

EP - 151

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -